{"disease":{"id":"aggressive-fibromatosis","name":"aggressive fibromatosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06204198","title":"Clinicopathological Features and Molecular Typing of Invasive Fibroma of Abdominal Wall","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Shandong Provincial Hospital","has_results":false},{"nct_id":"NCT03785964","title":"Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"SpringWorks Therapeutics, Inc.","has_results":true},{"nct_id":"NCT07176689","title":"Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"SpringWorks Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07170644","title":"A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"SpringWorks Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01981551","title":"Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03966742","title":"Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Rabin Medical Center","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}